Karachi: BF Bid Limited (BFBL), a subsidiary of Ferozsons Laboratories Limited, has formalized a contract manufacturing and supply agreement with Lucky Core Industries Limited (LCI) for the production and distribution of "Esopase IV 40 mg" and "Etipro IV 40 mg." According to information available from the Pakistan Stock Exchange (PSX), the agreement was announced in compliance with Section 96 of the Securities Act, 2015, and Clause 5.6.1(a) of PSX Regulations.
The partnership marks a strategic collaboration within the pharmaceutical sector, underscoring BFBL's capabilities in manufacturing and LCI's distribution network. The agreement is expected to enhance the availability of these critical medical products in the market, directly benefiting healthcare providers and patients alike.
This development is significant for both companies, reflecting BFBL’s expansion in contract manufacturing and LCI’s commitment to diversifying its product offerings. The news was disseminated to TREC Holders of the Exchange, ensuring transparency and compliance with regulatory requirements.